---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-259636"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2022-10-07T23:59:59+00:00"
generated_at: "2026-06-23T04:45:44.477556+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology enters amended license deal with Pfizer for ADC platform; pays $8M cash + $10M in stock

## Summary
- Pyxis pays Pfizer $8M cash and issues ~2.23M shares ($5M) on closing, plus $5M in shares 180 days later.
- Pfizer grants exclusive worldwide rights to FACT platform for ADCs targeting PYX-201 and PYX-203.
- Shares are unregistered, relying on Section 4(a)(2) exemption from the Securities Act.
- Post-issuance, Pyxis had ~35.1M shares outstanding as of October 6, 2022.

## SEC filing metadata
- accession: 0001193125-22-259636
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2022-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312522259636/0001193125-22-259636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312522259636/d407930d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-259636
- JSON: https://secwatch.observer/filing/0001193125-22-259636.json
- Plain text: https://secwatch.observer/filing/0001193125-22-259636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.